Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis

In recent years, significant changes have occurred in metastatic hormone-sensitive prostate cancer (mHSPC) management, where docetaxel and new androgen receptor pathway inhibitors (ARPI) have been shown to improve overall survival (OS) compared to androgen deprivation therapy (ADT). Recent data coul...

Full description

Bibliographic Details
Main Authors: Francesco Fiorica, Consuelo Buttigliero, Daniela Grigolato, Marco Muraro, Fabio Turco, Fernando Munoz, Marcello Tucci
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Current Oncology
Subjects:
triplet therapy
hormone-sensitive prostate cancer
high volume metastatic disease
de novo metastatic disease
systematic review
metanalysis
Online Access:https://www.mdpi.com/1718-7729/29/12/747

Internet

https://www.mdpi.com/1718-7729/29/12/747

Similar Items